ID   H460/CIS
AC   CVCL_A9CH
DR   cancercelllines; CVCL_A9CH
DR   Wikidata; Q108820357
RX   PubMed=11551417;
CC   Population: Caucasian.
CC   Doubling time: 1.9 days (PubMed=11551417).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0459 ! NCI-H460
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=11551417; DOI=10.1016/s0169-5002(01)00205-7;
RA   Yoon S.-S., Ahn K.-S., Kim S.-H., Shim Y.M., Kim J.;
RT   "In vitro establishment of cis-diammine-dichloroplatinum(II) resistant
RT   lung cancer cell line and modulation of apoptotic gene expression as a
RT   mechanism of resistant phenotype.";
RL   Lung Cancer 33:221-228(2001).
//